Background and purpose: Clinical decision support systems are a growing class of tools with the potential to impact healthcare. This study investigates the construction of a decision support system through which clinicians can efficiently identify which previously approved historical treatment plans are achievable for a new patient to aid in selection of therapy. Material and methods: Treatment data were collected for early-stage lung and postoperative oropharyngeal cancers treated using photon (lung and head and neck) and proton (head and neck) radiotherapy. Machine-learning classifiers were constructed using patient-specific feature-sets and a library of historical plans. Model accuracy was analyzed using learning curves, and historical treatment plan matching was investigated. Results: Learning curves demonstrate that for these datasets, approximately 45, 60, and 30 patients are needed for a sufficiently accurate classification model for radiotherapy for early-stage lung, postoperative oropharyngeal photon, and postoperative oropharyngeal proton, respectively. The resulting classification model provides a database of previously approved treatment plans that are achievable for a new patient. An exemplary case, highlighting tradeoffs between the heart and chest wall dose while holding target dose constant in two historical plans is provided. Conclusions: We report on the first artificial-intelligence based clinical decision support system that connects patients to past discrete treatment plans in radiation oncology and demonstrate for the first time how this tool can enable clinicians to use past decisions to help inform current assessments. Clinicians can be informed of dose tradeoffs between critical structures early in the treatment process, enabling more time spent on finding the optimal course of treatment for individual patients.
a b s t r a c t
Background and purpose: Clinical decision support systems are a growing class of tools with the potential to impact healthcare. This study investigates the construction of a decision support system through which clinicians can efficiently identify which previously approved historical treatment plans are achievable for a new patient to aid in selection of therapy. Material and methods: Treatment data were collected for early-stage lung and postoperative oropharyngeal cancers treated using photon (lung and head and neck) and proton (head and neck) radiotherapy. Machine-learning classifiers were constructed using patient-specific feature-sets and a library of historical plans. Model accuracy was analyzed using learning curves, and historical treatment plan matching was investigated. Results: Learning curves demonstrate that for these datasets, approximately 45, 60, and 30 patients are needed for a sufficiently accurate classification model for radiotherapy for early-stage lung, postoperative oropharyngeal photon, and postoperative oropharyngeal proton, respectively. The resulting classification model provides a database of previously approved treatment plans that are achievable for a new patient. An exemplary case, highlighting tradeoffs between the heart and chest wall dose while holding target dose constant in two historical plans is provided. Conclusions: We report on the first artificial-intelligence based clinical decision support system that connects patients to past discrete treatment plans in radiation oncology and demonstrate for the first time how this tool can enable clinicians to use past decisions to help inform current assessments. Clinicians can be informed of dose tradeoffs between critical structures early in the treatment process, enabling more time spent on finding the optimal course of treatment for individual patients.
Ó 2017 Published by Elsevier Ireland Ltd. Radiotherapy and Oncology 125 (2017) 392-397
The ideal radiotherapy treatment plan should be personalized, delivering a potentially curative tumor dose while minimizing toxicity based on the individual patient's specific anatomy and underlying medical condition. Traditionally, treatment planning decisions are guided by high-quality scientific studies that map quantities of radiation dose, e.g. Dose to 20% of the Lung Volume (V20) or prescribed dose, to the likelihood of tumor control and normal tissue toxicity. While the challenge of dosimetricallybased planning is a solvable computational problem, the underlying clinical challenge lies in understanding the best treatment plan that can be achieved for a specific patient, related to differences in patient anatomy, tradeoffs in the weighting of planning constraints, and conscious and unconscious biases on the part of the prescribing physicians [1] . Moreover, the process of creating a treatment plan requires close communications between practitioners with different areas of expertise in clinical medicine (physician), radiation delivery (physicist), and treatment planning software (dosimetrist).
Clinical decision support systems leverage the history of past decisions by a clinical team and quickly provide reference data informed by past successes at a given clinic or shared between clinics. Combined with contemporary machine learning (also known as artificial intelligence) algorithms and large data stores, these expert systems have begun to impact clinical practice, with examples such as the triage of patients in the Emergency Department [2] or highlighting of calcifications in breast mammography https://doi.org/10.1016/j.radonc.2017.10.014 0167-8140/Ó 2017 Published by Elsevier Ireland Ltd. [3] . A key element of these systems is the ability to augment clinicians' knowledge by processing previous decision records to identify those prior decisions and accompanying parameters that are relevant to the current patient. Together with new algorithm development, these systems promise to change the way decisions are made in medicine [4] [5] [6] . In radiation oncology, machine learning has been used in applications ranging from quality assurance to patient toxicity but clinical decision support systems (CDS) that empower physicians have not reached widespread use [7] [8] [9] [10] [11] [12] [13] .
This paper demonstrates a clinical decision support system utilizing machine-learning for patient-specific treatment planning in radiation oncology with the purpose of assisting the radiotherapy planning team in making better treatment plan decisions by leveraging past data. The key differentiation of our system from other ''knowledge based solutions" (KBS) to treatment planning is the focus on helping physicians navigate expectations about dosimetric tradeoffs before the treatment planning process. While other existing approaches focus on determining dose-volume histogram (DVH) expectations for individual organs at risk [14] [15] [16] , our approach allows prospective, expectant navigation of the inherent tradeoffs between those expectations. The CDS described here is aimed at helping physicians and the clinical team to determine the best course of treatment before expending resources on a lengthy treatment planning process, and to better define expectations among the radiation oncology team during the course of plan development. While treatment planning is still required, the knowledge ascertained from a CDS has the potential to guide therapy and decrease the time needed to reach an acceptable plan.
Methods

Data collection
Data from 2009 to 2015 from the University of Pennsylvania Health System was used in this Institutional Review Boardapproved retrospective study. The dataset was comprised of 104 consecutive early-stage lung cancer patients treated with stereotactic body radiation therapy (SBRT). Of these data, 81 received a prescription of 5000 cGy in 4 or 5 fractions to the planning target volume (PTV) (peripheral lesions), with the remaining receiving a prescription of 6000 cGy in 8 fractions (central lesions). An additional dataset was comprised of 40 patients with advanced-stage squamous cell carcinoma of the oropharynx who received postoperative proton radiotherapy. Of these data, 38 patients were prescribed between 6000 and 6600 cGy to the PTV (proton Radiobiological Effect Dose, RBE = 1.1). For each oropharynx patient, there also existed a volumetric modulated arc therapy (VMAT) clinical backup photon plan. Patients were identified through a database query (ARIA, Varian Medical Systems, CA). These data were exported, anonymized, and accumulated for processing by commercial software designed for the purposes of this study (QuickMatch, Siris Medical, CA).
Patient treatment plan classification
The goal of the CDS system is to match the current patient to previously treated patients with similar characteristics, such that previously achieved treatment plans and tradeoffs can be explored. This is represented schematically in Fig. 1 . Current planning approaches either do not algorithmically use past data ( Fig. 1A) , or use past data to understand trends from DVH subpopulations ( Fig. 1B) , primarily as a quality assurance tool. In contrast, plan classification identifies discrete historical plans that can include dose tradeoffs between the target and various organs-at-risk. The requirements for plan classification are an accurate classification algorithm combined with a knowledge database of previous patient treatments. With a sufficiently large database, various achievable results will be proposed by the algorithm such that the clinical team has multiple reference points to use for optimally choosing the appropriate dose trade-offs for a given patient ( Fig. 1C and E) .
Consider a database of plans, P, from which we seek matches to a specific plan p, where matching is defined according to a dissimilarity index of the dosimetric indices between plans. Addressing this problem as a classification problem similar to nearest neighbor classification, we would like to find the plans in P that are closer to p in terms of the dissimilarity index. A probability threshold, s, is set for the dissimilarity index, and prior treatments that are within the threshold produce treatment plan matches. Formally, the subset P p # P of plans in P that matches plan p can be defined as:
where f are the features, d are the dosimetric indices, and the indices ''i" denote different plans in the database. For the current patient, F p and D p are the features and dosimetric indices. A threshold, s, is set for classification, and prior treatments that are within the threshold produce treatment plan matches. This probability threshold defines achievability and incorporates known sources of dosimetric variability in planning, including the repeatability of the treatment plan produced by the treatment planning system, v TPS , and the variation in treatment planning preference between clinicians, v C . The variability in the treatment planning system is found empirically by repeatedly running the treatment planning system for a given set of dosimetric objectives and priorities on exemplary treatment plans. The variability in clinician preference can be learned by calculating the variability in prediction for prediction models built on different subgroups of the dataset, stratified by, for example, treatment planner or physician. This threshold is defined as:
More specifically, the dissimilarity between the new patient plan p and a historical patient plan P i is determined by calculating the difference between the j dosimetric indices of patient p and patient P i . A historical patient is a match if,
For an historical patient, d i are the dosimetric indices from the historical plan. For the new patient,
where f p are the generated features for the new patient. As noted above, a boosting framework is used to predict the dosimetric indices:
where T(f) is a weak learner. Because of the modern machine learning approach that was used (boosting) and our extensive featureset, the summation in Eq. (5) is over thousands of decision trees that take input from thousands of features. Therefore, a more detailed description of the function represented in Eq. (5) is not practical in this manuscript, and powerful computation is needed to obtain its value. Boosting is a well-known technique in modern machine learning and has been proven to be one of the most accurate, but powerful computing is required to generate the result [19] . Creating the features that account for data variability is a critical aspect of an accurate classifier; this process is often viewed as the most important aspect of a machine learning algorithm [19] . For an accurate feature set, we perform analysis on DICOM images, medical record data (e.g. ICD-9/10 diagnosis codes), radiationtransport parameters (e.g. beam energy), and physician treatment intent (e.g. prescription). Several important feature-sets are shown below in Table 1 . Additionally, the dosimetric indices for the gross tumor volume (GTV), clinical target volume (CTV), PTV, and organs at risk (OARs) are analyzed for each plan in the knowledge database and aggregated to form the patient response or treatment plan matrix. In this work, the predictive models are built using a boosting framework which internally incorporates feature selection to avoid overfitting [20] and that has been previously used in Radiation Oncology data [9] .
Model assessment
An adequately large and heterogeneous database is needed to ensure accuracy in plan classification and to ensure identification of previously achievable treatment plans. To prevent over-fitting during model creation, statistical models were constructed utilizing five-fold cross-validation techniques for each dataset [19] .
Learning curves were constructed to analyze the effect of dataset size on dosimetric model accuracy and misclassification error; this technique is a standard method in the machine learning literature for analyzing model error with respect to dataset size [19] . For all dosimetric indices, a decreasing exponential was fit to the data and extrapolated to analyze model error beyond the study dataset size. In general, as the dataset size increases, the model is able to capture the heterogeneity in the data, and thus generate more accurate predictions. For classification, a larger dataset enables more potential past patient treatments for classification.
In order to validate the classification of a treatment plan (to find a match), validation datasets consisting of 10 SBRT lung patients and 7 head and neck (HNC) patients were used. These patient plans were independent of the original data (104 lung plans and 40 head and neck plans) that were used to construct the statistical models, 
Table 1
Feature-set categories used to predict dose for a radiation treatment plan.
Feature category Example features
Anatomical information Distance, volume, geometric relationship, and importance of structures and surrounding structures Medical record ICD-9/10 code, gender, ethnicity Treatment intent Fractionation schedule, treatment margin, number of beams/arcs, and the clinicians who are part of the team creating the radiation treatment plan Radiation transport Penumbra, aperture, incident angle, beam energy, radiation type (proton vs photon), depth of structure, and existence of bolus and thus represent the clinical scenario of new patients being assessed by the system. Doses were predicted for each of the validation patients based on the calculated features and the results were compared with the known validation patient doses.
Results
Dosimetric model accuracy and treatment plan misclassification error were investigated using learning curve analyses [19] . Fig. 2 shows the learning curves for (A) lung SBRT, (B) HNC photon-based IMRT, and (C) HNC proton therapy, for all dosimetric indices. The discrete model error for the dosimetric index that required the largest dataset (amount of learning) is overlaid as circles on the appropriate extrapolated curve. For lung patients, this index is the maximum dose to the ipsilateral brachial plexus; for HNC photon it is the mean dose to the contralateral submandibular gland; for HNC proton, it is the mean dose to the ipsilateral parotid. It can be seen that in order for dose prediction error to meet a 2 Gy threshold, chosen as approximately 10% of the maximum dose constraints for the serial structures, a library of 97 patients is needed for lung, 68 patients for HNC photon, and 92 patients for HNC proton.
The validation datasets described above (10 lung patients, 7 HNC patients) were used to build plan classification learning curves to determine the effect of database size on misclassification error; these validation patients were not used in constructing the statistical model. Fig. 3A shows the misclassification error for SBRT lung plans, in which a dataset size of 45 was needed to correctly classify all patients. For HNC photon plans, a dataset size of approximately 60 patients was needed for accurate classification. For HNC proton plans, a dataset size of 30 patients was needed.
The classification algorithm was used to investigate the number of potential treatment plan matches for each patient in the valida- tion sets. The same patient libraries previously used to create the classification models were used as potential matches for the validation set. Fig. 4 shows the patient matches (columns) available for each of the validation patients (rows) for lung SBRT, HNC photon-based IMRT, and HNC proton therapy, respectively. Green lines indicate which library patients matched to the validation patients; gray regions indicate that the corresponding library patients were not a match.
A case of a patient with several applicable treatment dose tradeoffs is shown in Fig. 5. Fig. 5A presents the CT of a patient with stage I non-small cell lung cancer that is matched to the library. The dosimetric indices of two achievable matches are shown in Fig. 5B ; values that are above the treatment constraint limit are marked in red. The treatment plans for these matched patients are shown below, specifically patient 8 in Fig. 5C and patient 92 in Fig. 5D. Fig. 5B shows two different potential outcomes in which a variety of outcomes may be explored. In the case of patient 8, the decision was made historically to reduce the chest wall D30cc below 25 Gy. This resulted in increased dose to the heart. Conversely, an alternative treatment plan outcome is shown for patient 92, where the heart D15cc was reduced compared to that of patient 8 (7. 38 Gy decreased to 4.29 Gy), but with an increased dose to the chest wall (24.9 Gy increased to 31.1 Gy) and the same PTV coverage (50.3 Gy). It is important to note that although the geometric position of the tumor on the validation set is not exactly the same as that of the patient in panel D, the algorithm effectively identifies the tradeoff between dose to chest wall and dose to the heart for the case under interrogation. This tradeoff is visually translated for the clinician by showing previous cases where the compromises were made. A diagram such as that presented in Fig. 5 can also assist a physician in informing a patient about the inherent tradeoffs of a given clinical decision. This could shift the current clinical decision making process to one in which both physicians and patients may actively visualize the tradeoffs and implications.
Discussion
The power of decision support is the ability to connect a current patient to past decisions [2] , which can be recalled from within the same institution or across different institutions. The impact is that decision support tools can enable investigation of prior applicable decisions in an efficient manner by aiding expert opinion and reducing the labor required to reach decision points. With more expertise spent on the clinical decisions themselves, this approach has the potential to improve efficiency, reduce costs, and importantly improve patient outcomes.
Indeed, decision support systems across oncology have proven to be capable of having impact on workflow and quality of care. For example, predictive systems have been used to estimate the risk of breast lesion malignancy [3] , predict the outcomes of patients with lung cancer treated with chemoradiation therapy [9, 13] , predict the survival of patients with skeletal metastases [21] or predict which radiotherapy technique is more appropriate [12, 22, 23] . Brodin et al. developed a decision support tool to investigate dose-response relationships in Hodgkin's lymphoma, while Cheng et al. have developed decision support systems to evaluate the choice of proton vs photon [24, 25] ; this tool additionally aided in the optimization of the treatment plan. Others have proposed predictive models of radiotherapy treatment response for genitourinary and thoracic sites [9, 13] . Uniquely, the work described herein is the first demonstration of a tool to enable patientspecific dosimetric decision support in a generalized manner across multiple anatomical sites, multiple treatment modalities, and multiple fractionation schemes. In that regard, it is important to highlight the differences between knowledge based solutions (KBS) that to date have been used in radiation oncology and the unique approach presented here. KBS focuses on finding thresholds for error bars and is an excellent tool to evaluate the quality of the planning process [14] [15] [16] . In this paper, we demonstrate the novel feasibility of providing matches, which can aid physicians and patients in decision making prior to the treatment planning process [26] .
While the ability to investigate dose trade-offs offers similar functionality to the 'pareto' approach to treatment planning [27] , a significant difference is that historical treatment decision support can recall previous treatment decisions, acting as reference to pastapproved decisions, and may be applied across institutions.
There are drawbacks to the proposed technique related to database size and quality. While the database only includes clinicallyapproved plans, there is an inherent variability in the quality of these cases; furthermore, an insufficient database size can restrict the clinician to a match that may be suboptimal. In addition, a reduced number of matches reduces the number of dose tradeoffs that can be explored, though these matches can still provide the clinician with information that could benefit decision making. A larger database, especially across multiple clinics, would provide a more expansive group of matches which would capture better quality plans and enable exploration of dosimetric trade-offs in greater resolution.
One limitation of the current study is that some of the learning curves needed to be extrapolated to reach the desired reported error. While this is standard practice in the machine learning literature [19] , there is uncertainly in the exact numbers of patient data needed to reach the stated error for such curves.
This study demonstrates the utility of the data-driven machine learning strategy in multiple anatomical sites, fractionation schemes, and treatment modalities. It is, however, limited to the datasets studied herein. Future investigations will assess the impact in additional anatomical sites, fractionation schemes, and treatment modalities, as well as the application to treatment decisions such as which technique or delivery modality is optimal. Further work will also investigate the effect of dataset size to matching; it is anticipated that the impact of this technique will strengthen with larger dataset sizes and across multiple institutions, as the number of matches and thus the degree of clinical insight will increase. Additionally, future work will investigate the impact on enabling remote consultation and remote planning.
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